A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 269-276

  Hertogs, Kurt ^a   De Béthune, Marie Pierre ^b   Miller, Veronica ^c   Ivens, Tania ^b   Schel, Patricia ^a   Van Cauwenberge, Anja ^a   Van Den Eynde, Christel ^a   Van Gerwen, Veerle ^a   Azijn, Hilde ^b   Van Houtte, Margriet ^a   Peeters, Frank ^a   Staszewski, Schlomo ^c   Conant, Marcus ^d   Bloor, Stuart ^e   Kemp, Sharon ^e   Larder, Brendan ^e   Pauwels, Rudi ^a,b  

^a Virco BVBA   (Belgium)

^b TIBOTEC BVBA   (Belgium)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Conant Medical Group ^*  (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; PROTEINASE INHIBITOR; R 91767; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIVIRAPINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; BIOASSAY; DRUG RESISTANCE; GENETIC RECOMBINATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS RECOMBINANT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REASSORTANT VIRUSES; REPRODUCIBILITY OF RESULTS;

EID: 0344474694     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Boucher, C., W. Keulen, T. Van Bommel, M. Nijhuis, D. De Jong, M. De Jong, P. Schipper, and N. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
2. Carpenter, C., M. Fischi, S. Hammer, M. Hirsch, D. Jacobsen, D. Katzenstein, J. Montaner, D. Richman, M. Saag, R. Schooley, M. Thompson, S. Vella, P. Yeni, and P. Volberding. 1996. Antiretroviral therapy for HIV infection. JAMA 276:146-154.
3. Condra, J., D. Holder, W. Schleif, O. Blahy, R. Danovich, L. Gabryelski, D. Graham, D. Laird, J. Quintero, A. Rhodes, H. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. Chodakewitz, P. Deutsch, R. Leavitt, F. Massari, J. Mellors, K. Squires, R. Steigbigel, H. Teppler, and E. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
4. Condra, J., W. Schlief, O. Blahy, L. Gabryelski, D. Graham, J. Quintero, A. Rhodes, H. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. Squires, P. Deutsch, and E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 375:569-571.
5. Conway, B., V. Montessori, D. Rouleau, J. Montaner, S. Fransen, A. Shillington, and D. Mayers. 1997. Primary lamivudine resistance in acute HIV infection, abstr. 103. p. 68. In Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
6. Craig, J., I. Duncan, D. Hockley, C. Grief, N. Roberts, and J. Mills. 1991. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antivir. Res. 16:295-305.
7. de Béthune, M. P., K. Hertogs, K. Andries, P. Stoffels, J. Van Roey, P. Schel, A. Van Cauwenberge, C. Van den Eynde, M. De Brabander, J. De Cree, and R. Pauwels. 1996. Monitoring of anti HIV-1 therapy by drug resistance phenotyping (RT-Antivirogram™) and plasma viral load determination: a case study. Antivir. Ther. 1(Suppl. 1):42.
8. Dewar, R., H. Highbarger, M. Sarmiento, J. Todd, M. Vasudevachari, R. Davey, J. Kovacs, N. Salzman, H. Lane, and M. Urdea. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
9. Dorsey, B., R. Levin, S. McDaniel, J. Vacca, J. Guare, P. Darke, J. Zugay, E. Emini, W. Schleif, J. Quintero, J. Lin, I. Chen, M. Holloway, P. Fitzgerald, M. Axel, D. Ostovic, P. Anderson, and J. Huff. 1994. L-735,524 - the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
10. Eberle, J., B. Bechowsky, D. Rose, U. Hauser, K. Vonderhelm, L. Gurtler, and H. Nitschko. 1995. Resistance of HIV type-1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11:671-676.
11. Gingeras, T., G. Mamtora, N. Shen, J. Drenkow, M. Winters, and T. Merigan. 1996. Genetic analysis of HIV-1 plasma using high density oligonucleotide arrays and dideoxynucleotide sequencing. Antivir. Ther. 1(Suppl. 1):42.
12. Hertogs, K., M. Conant, P. Schel, A. Van Cauwenberge, M. P. de Béthune, and R. Pauwels. 1996. The RT-Antivirogram™: a rapid and accurate method to determine phenotypic (multi-) drug resistance in plasma of patients treated with various HlV-1 RT inhibitors. Antivir. Ther. 1(Suppl. 1):40.
13. Ho, D., A. Neumann, A. Perelson, W. Chen, J. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
14. Imamichi, H., Y.-M. Zhang, H. C. Lane, J. Fallon, and N. P. Salzman. 1997. Continued evolution of HIV-1 during combination therapy despite levels of HIV-1 RNA <500 copies/ml, abstr. 63, p. 41. In Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
15. Iversen, A., R. Shafer, K. Wehrly, M. Winters, J. Mullins, B. Chesebro, and T. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
16. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
17. Jellinger, R., R. Shafer, and T. Merigan. 1997. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. J. Infect. Dis. 175:561-566.
18. Kaye, S., C. Loveday, and R. Tedder. 1992. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J. Med. Virol. 37:241-246.
19. Kellam, P., and B. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
20. Kempf, D., K. Marsh, J. Denissen, E. McDonald, S. Vasavanonda, C. Flentge, B. Green, L. Fino, C. Park, X. Kong, N. Wideburg, A. Saldivar, L. Ruiz, W. Kati, H. Sham, T. Robins, K. Stewart, A. Hsu, J. Plattner, J. Leonard, and D. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
21. Kusumi, K., B. Conway, S. Cunningham, A. Berson, C. Evans, A. Iversen, D. Colvin, M. Gallo, S. Coutre, E. Shpaer, D. Faulkner, A. De Ronde, S. Volkman, C. Williams, M. Hirsch, and J. Mullins. 1992. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J. Virol. 66:875-585.
22. Larder, B., G. Darby, and D. Richman. 1989. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 243:1731-1734.
23. Larder, B., and S. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine. Science 246:1155-1158.
24. Larder, B., S. Kemp, and R. Harrigan. 1991. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
25. Larder, B., A. Kohli, P. Kellam, S. Kemp, M. Kronick, and R. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
26. Luiz, M., L. Janini, D. Pieniazek, J. Peralta, M. Schechter, A. Tanuri, A. Vicente, N. Della Torre, N. Pieniazek, C. Luo, M. Kalish, G. Schochetman, and M. Rayfield. 1996. Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes 13:69-81.
27. Martinez-Picado, J., L. Sutton, A. Hoes Helfant, A. Savara, J. Kaplan, and R. D'Aquila. 1997. Novel clonal analyses of resistance to HIV-1 RT and protease inhibitors, abstr. 45, p. 30. In Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
28. Mayers, D., D. Gallahan, G. Martin, W. Emmons, R. Chung, K. Spooner, J. Newton, N. Aronson and O. Weislow. 1997. Drug resistance genotypes from plasma virus of HIV-1 infected patients failing combination drug therapy, abstr. 80, p. 52. In Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
29. Mellors, J., C. Rinaldo, P. Gupta, R. White, J. Todd, and L. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma. Science 272:1167-1170.
30. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. Schipper, H. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. Granneman, D. Ho, C. Boucher, J. Leonard, D. Norbeck, and D. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
31. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
32. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
33. Perelson, A., A. Neumann, M. Markowitz, J. Leonard, and D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
34. Richman, D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. Spector, J. Sullivan, S. Cheeseman, K. Barringer, and D. Pauletti. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
35. Saag, M., G. Shaw, D. Richman, and P. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2:625-629.
36. Sardana, V., E. Emini, L. Gotlib, D. Graham, D. Lineberger, W. Long, A. Schlabach, J. Wolfgang, and J. Condra. 1992. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors. J. Biol. Chem. 267:17526-17530.
37. Schinazi, R., B. Larder, and J. Mellors. 1996. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 4:95-107.
38. Schmit, J. C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A. Vandamme. 1996. Multiple drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
39. Shafer, R., A. Iversen, M. Winters, E. Aguiniga, D. Katzenstein, and T. Merigan. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172:70-78.
40. Shi, C., and J. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785.
41. St. Clair, M., J. Martin, G. Tudor-Williams, M. Bach, L. Vavro, D. King, P. Kellam, S. Kemp, and B. Larder. 1991. Resistance to didanosine and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
42. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. Schinazi, and R. Rossau. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
43. Tisdale, M., S. Kemp, N. Perry, and B. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibi-tors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
44. Tisdale, M., R. Meyers, B. Maschera, N. Parry, N. Oliver, and E. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
45. van Gemen, B., R. van Beuningen, A. Nabbe, D. van Strijp, S. Jurriaans, P. Lens, and T. Kievits. 1994. A one-tube quantitative RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J. Virol. Methods 49:157-167.
46. Wei, X., S. Ghosh, M. Taylor, V. Johnson, E. Emini, P. Deutsch, J. Lifsin, S. Bonhoeffer, M. Nowak, B. Hahn, M. Saag, and G. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 375:117-122.
47. Zhang, D., A. Caliendo, J. Eron, K. DeVore, J. Kaplan, M. Hirsch, and R. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1428-1432.